In our ALTTO analysis, PREDICT highly underestimated patients’ OS; this finding was consistent across all patient subgroups, with highest absolute differences for patients with hormone receptor-negative disease, nodal involvement, and large tumor size. This evidence concerns the gene NR4A1 and neoplasm.